Serum vascular endothelial growth factor and its receptor level in patients with chronic obstructive pulmonary disease

European Cytokine Network

Volumn 17, Issue 1, 2006, Pages 75-79

  Kierszniewska Stepień, Dorota ^a   Pietras, Tadeusz ^a   Górski, Pawel ^a   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

COPD; Pulmonary disease; Vascular remodelling; VEGF; VEGF Receptors

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC OBSTRUCTIVE LUNG DISEASE; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MALE; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33746037285     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Barnes PJ. COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 2004; 4: 263.
2. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655.
3. Mandega RM, Fung YC, Huang W, et al. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc Res 2004; 68: 75.
4. Howell K, Ooi H, Preston R, et al. Structural basis of hypoxic pulmonary hypertension: the modifying effect of chronic hypercapnia. Exp Physiol 2004; 89: 66.
5. Haddad JJ. Science review: redox and oxygen-sensitive transcription factors in the regulation of oxidant-mediated lung injury: role for hypoxia-inducible factor-1alpha. Crit Care 2003; 7: 47.
6. Louzier V, Raffestin B, Leroux A, et al. Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2003; 284: L926.
7. Ferrara N. Vascular Endothelial Growth Factor: Basic Science and Clinical Progress. Endocr Rev 2004; 25: 581.
8. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001; 22: 201.
9. Fabbri LM, Hurd SS. Global strategy for diagnosis, management and prevention of COPD: 2003 update. Eur Resp J 2003; 22: 1.
10. Berglund E, Birath G, Bjure J, et al. Spirometric studies in normal subject. Acta Med Scand 1963; 173: 185.
11. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2689.
12. Santos S, Peinado VI, Ramirez J, et al. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1250.
13. Kranenburg AR, de Boer WI, Alagappan VK, et al. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 106.
14. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851.
15. Ning W, Li CJ, Kaminski N, et al. Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004; 101: 14895.
16. Jeffrey PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Care Med 2001; 164: S28.
17. Saetta M, Turato G, Maestrelli P, et al. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Care Med 2001; 163: 1304.
18. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and VEGF Receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798.
19. Voelkel NF, Hoeper N, Msaloney J, et al. Vascular endothelial growth factor in pulmonary hypertension. Ann N Y Acad Sci 1996; 796: 186.
20. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003; 28: 555.
21. Kanazawa H, Asai K, Hirata K, et al. Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med 2003; 114: 354.
22. Sakao S, Tatsumi K, Hashimoto T, et al. Vascular endothelial growth factor and the risk of smoking-related COPD. Chest 2003; 124: 323.
23. Conklin BS, Zhao W, Zhong DS, et al. Nicotine and cotinine upregulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol 2002; 160: 413.
24. Barbera JA, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149: 423.
25. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF Receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000; 106: 1311.
26. Petty TL. COPD in perspective. Chest 2002; 121: 116S.
27. Tuder RM,Yasanori Kasahara Y, Voelkel NF. Inhibition of vascular endothelial growth factor receptors causes emphysema in rats. Chest 2000; 117: 281S.
28. Tuder RM, Zhen L, Cho CY, et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol 2003; 29: 88.